OssDsign AB

OssDsign AB has a market capitalization of 459.1 million SEK and a price-to-book ratio of 2.04, indicating that the market values the company at a premium to its book value. The company's liquidity position is characterized by a current ratio of 6.33, suggesting strong short-term liquidity, but its operating cash flow of -46.65 million SEK indicates a significant outflow of cash from operations.

Profitability metrics show a challenging financial position for OssDsign. The company reported a net loss of 15.69 million SEK and an operating loss of 15.29 million SEK. Return on equity is negative at -6.98%, and return on assets is also negative at -5.12%, both significantly below industry norms for a profitable medical equipment company.

Geographically and segment-wise, OssDsign's revenue concentration is not disclosed in the available data. However, the company's operations are primarily in the healthcare services and equipment sector, with no detailed breakdown of revenue by geographic region or product segment provided in the financial snapshot.

Looking at the growth trajectory, OssDsign's revenue in the latest period was 29.74 million SEK, with analysts estimating a mean revenue of 199.33 million SEK for the next period. This suggests a potential growth of 575% in revenue, although the company is currently reporting a net loss and negative operating cash flow.

The risk assessment for OssDsign indicates a medium liquidity risk and a low dilution risk. The company has a debt-to-equity ratio of 0.01, indicating minimal leverage, but its net cash position is negative after subtracting total debt. The risk of dilution is low, with no significant dilution potential identified in the basic shares outstanding.

Recent events and filings show that OssDsign is under analyst coverage with a mean price target of 13.00 SEK, significantly higher than the current market price of 4.15 SEK. The company's earnings per share (EPS) are expected to remain negative, with a mean estimate of -0.36 SEK, slightly improved from the last actual EPS of -0.38 SEK.

Revenue grew at a 54.4% CAGR over four years, demonstrating strong top-line expansion momentum for the company.

Analysts project 225.8% upside potential, with a mean price target of 13.0 SEK versus the current 3.99 SEK price.

Gross profit surged to 173.5 million SEK in FY2026, indicating significant improvement in core product profitability margins.

Long-term debt decreased substantially to 1.4 million SEK in FY2026, reflecting a strengthened balance sheet and reduced leverage.

Cash conversion ratio of 2.97 ranks as best-in-class compared to the 0.84 median within the medical equipment cohort.

The company reported a net loss of 51.0 million SEK in FY2026, continuing a pattern of persistent unprofitability.

Revenue kr 36.9M, −17,1% YoY; Operating income −6,1% YoY.

• ▍Revenue kr 36.9M, −17,1% YoY
• ▍Operating income −6,1% YoY
• ▍Net income +21,3% YoY
• ▍Net margin -31.1%

Revenue kr 45.1M, +8,9% YoY; Operating income −76,1% YoY.

• ▍Revenue kr 45.1M, +8,9% YoY
• ▍Operating income −76,1% YoY
• ▍Net income −70,7% YoY
• ▍Net margin -49.4%

Revenue kr 44.0M, +23,2% YoY; Operating income +43,7% YoY.

• ▍Revenue kr 44.0M, +23,2% YoY
• ▍Operating income +43,7% YoY
• ▍Net income +40,8% YoY
• ▍Net margin -13.1%

Revenue kr 46.5M, +56,4% YoY; Operating income +54,6% YoY.

• ▍Revenue kr 46.5M, +56,4% YoY
• ▍Operating income +54,6% YoY
• ▍Net income +46,8% YoY
• ▍Net margin -17.9%

Revenue kr 44.5M; Operating income -kr 12.7M.

• ▍Revenue kr 44.5M
• ▍Operating income -kr 12.7M
• ▍Net margin -32.8%

Revenue kr 41.4M; Operating income -kr 12.3M.

• ▍Revenue kr 41.4M
• ▍Operating income -kr 12.3M
• ▍Net margin -31.5%

Revenue kr 35.7M; Operating income -kr 9.8M.

• ▍Revenue kr 35.7M
• ▍Operating income -kr 9.8M
• ▍Net margin -27.3%

Revenue kr 29.7M; Operating income -kr 15.3M.

• ▍Revenue kr 29.7M
• ▍Operating income -kr 15.3M
• ▍Net margin -52.8%

Revenue kr 180.2M, +34,5% YoY; Operating income +5,4% YoY.

• ▍Revenue kr 180.2M, +34,5% YoY
• ▍Operating income +5,4% YoY
• ▍Net income −2,7% YoY
• ▍Free cash flow −18,0% YoY
• ▍Net margin -28.3%

Revenue kr 133.9M, +19,4% YoY; Operating income +61,3% YoY.

• ▍Revenue kr 133.9M, +19,4% YoY
• ▍Operating income +61,3% YoY
• ▍Net income +62,0% YoY
• ▍Free cash flow +64,2% YoY
• ▍Net margin -37.1%

Revenue kr 112.2M, +96,8% YoY; Operating income −31,7% YoY.

• ▍Revenue kr 112.2M, +96,8% YoY
• ▍Operating income −31,7% YoY
• ▍Net income −31,3% YoY
• ▍Free cash flow −36,3% YoY
• ▍Net margin -116.3%

Revenue kr 57.0M, +79,6% YoY; Operating income −8,1% YoY.

• ▍Revenue kr 57.0M, +79,6% YoY
• ▍Operating income −8,1% YoY
• ▍Net income −5,8% YoY
• ▍Free cash flow −6,6% YoY
• ▍Net margin -174.4%